Phoenix Neurological Associates

Phoenix Neurological Associates

ALS

A Pilot Trial of Pioglitazone HCl and Tretinoin in ALS: Cerebrospinal Fluid Biomarkers to Monitor Drug Efficacy and Predict Rate of Disease Progression

Clinical recognition and management of amyotrophic lateral sclerosis

A Pilot Trial of Pioglitazone HCl and Tretinoin in ALS: Cerebrospinal Fluid Biomarkers to Monitor Drug Efficacy and Predict Rate of Disease Progression,

Brachial amyotrophic diplegia: a slowly progressive motor neuron disorder.

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

Whole-genome analysis of sporadic amyotrophic lateral sclerosis.

A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.

A pilot trial of memantine and riluzole in ALS: Correlation to CSF biomarkers

CIDP

Treatment of IgM antibody associated polyneuropathies using rituximab.
IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab.

Distal acquired demyelinating symmetric neuropathy.

Clinical spectrum of chronic acquired demyelinating polyneuropathies.

Chronic Inflammatory Demyelinating Polyneuropathy

Dermatomyositis

Acthar in Dermatomyositis and Polymyositis Treatment Registry: An Interim Analysis (593k PDF)
Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series.
History of dermatomyositis
Rituximab in the treatment of dermatomyositis: an open-label pilot study.

Guillain Barre

Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy.

Inclusion Body Myositis

Interim Analysis of A Pilot Trial of Natalizumab in Inclusion Body Myositis (458k PDF)

Pilot trial of etanercept in the treatment of inclusion-body myositis.

Muscular Dystrophy

Clinical and genetic aspects of distal myopathies.

Multiple Sclerosis

Exploring the Clinical Course of Hair Thinning Associated With Teriflunomide: An Update to the Teriflunomide Real-World Case Series (792k PDF)

ALLOW – A Phase 3b Trial Characterising Flu-like Symptoms in Patients Transitioning to Pegylated Interferon Beta-1a: Interim Analysis of all Patients

The Delphi Method on Peginterferon Beta-1 Injection Site Reactions and Management Strategies in the Relapsing-Remitting Multiple Sclerosis ALLOW Study

Glatiramer acetate in the reduction of relapse frequency in multiple sclerosis

Clinical recognition and management of amyotrophic lateral sclerosis.

Clinical, biochemical and imaging parameters that may be predictive of high disease activity, rapid progression or increased disability in multiple sclerosis.

Glatiramer acetate in the reduction of relapse frequency in multiple sclerosis.

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Avonex Combination Trial in relapsing–remitting MS: rationale, design and baseline data.

Myasthenia Gravis

Retrospective review of the safety of Hizentra in neuromuscular patients with renal failure (845k PDF)

Management of myasthenia gravis.

Peripheral Neuropathy

Usefulness of Skin Biopsies in the Evaluation and Management of Patients with Suspected Small Fiber Neuropathy.

Chronic cryptogenic sensory polyneuropathy: clinical and laboratory characteristics.
Challenges in the identification of cobalamin-deficiency polyneuropathy.

Treatment of IgM antibody associated polyneuropathies using rituximab.

IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab.

Chronic acquired demyelinating polyneuropathies.

Treatment recommendations in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia.

Peripheral neuropathies in Waldenström’s macroglobulinaemia.

Peripheral neuropathy in an outpatient cohort of patients with Sjögren’s syndrome.

Polymyositis

Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series

Inflammatory myopathy with cytochrome oxidase negative muscle fibers: methotrexate treatment.

Small Fiber Neuropathy

Small Fiber Neuropathy in Patients Meeting Diagnostic Criteria for Fibromyalgia

Other

Muscle channelopathies.

Footer

Notice Of Non-Descrimination

Notice of Non-Discrimination


Phoenix Neurological Associates complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Phoenix Neurological Institute does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex. Phoenix Neurological Associates:
  • Provides free aids and services to people with disabilities to communicate effectively with us, such as:
    • Qualified sign language interpreters
    • Written information in other formats (large print, audio, accessible electronic formats, other formats)
  • Provides free language services to people whose primary language is not English, such as:
    • Qualified interpreters Information written in other languages
If you need these services, contact Robert Chiffelle, COO. If you believe that Phoenix Neurological Associates has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Robert Chiffelle, COO, 5090 N. 40 St., Suite 250, Phoenix, Az. 85018, Telephone number 602-258-3354, Fax 602-258-3368, Rchiffelle@pnal.net. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, Robert Chiffelle, COO is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:

U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201 1-800-368-1019, 800-537-7697 (TDD)

Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html

Anuncio de No Discrimina

Phoenix Neurological Associates cumple con las leyes federales de derechos civiles aplicables y no discrimina por motivos de raza, color, nacionalidad, edad, discapacidad o sexo. [Name of covered entity] no excluye a las personas ni las trata de forma diferente debido a su origen étnico, color, nacionalidad, edad, discapacidad o sexo. Phoenix Neurological Associates:
  • Proporciona asistencia y servicios gratuitos a las personas con discapacidades para que se comuniquen de manera eficaz con nosotros, como los siguientes:
    • Intérpretes de lenguaje de señas capacitados.
    • Información escrita en otros formatos (letra grande, audio, formatos electrónicos accesibles, otros formatos).
  • Proporciona servicios lingüísticos gratuitos a personas cuya lengua materna no es el inglés, como los siguientes:
    • Intérpretes capacitados.
    • Información escrita en otros idiomas.
Si necesita recibir estos servicios, comuníquese con Robert L. Chiffelle, COO. Si considera que Phoenix Neurological Associates no le proporcionó estos servicios o lo discriminó de otra manera por motivos de origen étnico, color, nacionalidad, edad, discapacidad o sexo, puede presentar un reclamo a la siguiente persona: Robert Chiffelle, COO, 5090 N. 40 St., Suite 250, Phoenix, Az. 85018, Telephone number 602-258-3354, Fax 602-258-3368, Rchiffelle@pnal.net. Puede presentar el reclamo en persona o por correo postal, fax o correo electrónico. Si necesita ayuda para hacerlo, Robert L. Chiffelle, COO está a su disposición para brindársela. También puede presentar un reclamo de derechos civiles ante la Office por Civil Rights (Oficina de Derechos Civiles) del Department of Health and Human Services (Departamento de Salud y Servicios Humanos) de EE. UU. de manera electrónica a través de Office for Civil Rights Complaint Portal, disponible en https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, o bien, por correo postal a la siguiente dirección o por teléfono a los números que figuran a continuación:

U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201 1-800-368-1019, 800-537-7697 (TDD)

Puede obtener los formularios de reclamo en el sitio web http://www.hhs.gov/ocr/office/file/index.html.

©2017 Phoenix Neurology Associates. All rights reserved. | Powered By: Medical Marketing 360®

Powered by Top Rated Local®

uxicached